ORGANON PHARMA (UK) LIMITED
Get an alert when ORGANON PHARMA (UK) LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Next accounts due
2026-09-30 (in 4mo)
Last filed for 2024-12-31
Confirmation statement due
2026-07-24 (in 2mo)
Last made up 2025-07-10
Watchouts
None on the register
Cash
—
Latest balance sheet
Net assets
£105M
-0.1% vs 2023
Employees
713
+5.6% vs 2023
Profit before tax
£8M
-10.1% vs 2023
Net assets
2-year trend · vs Health Care median
Accounts
2-year trend · latest reflected 2024-12-31
| Metric | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Turnover | £138,910,000 | £153,007,000 | |
| Operating profit | £11,119,000 | £11,010,000 | |
| Profit before tax | £8,735,000 | £7,850,000 | |
| Net profit | £6,240,000 | -£2,023,000 | |
| Cash | £11,616,000 | — | |
| Total assets less current liabilities | £113,498,000 | £116,734,000 | |
| Net assets | £105,040,000 | £104,964,000 | |
| Equity | £105,040,000 | £104,964,000 | |
| Average employees | 675 | 713 | |
| Wages | £36,352,000 | £40,769,000 |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating margin | 8.0% | 7.2% | |
| Net margin | 4.5% | -1.3% | |
| Return on capital employed | 9.8% | 9.4% | |
| Current ratio | 1.08x | 0.88x | |
| Interest cover | 4.57x | 3.45x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Audit & accounting basis
- Accounting basis
- FRS 102
- Reporting scope
- Standalone (parent only)
- Auditor
- PricewaterhouseCoopers LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“The Company's parent (Organon & Co.) and Company's financial position allows the Company to maintain liquidity and access capital markets through their ultimate parent company, as needed. After reviewing the company's forecasts and projections, the company is still in an overdraft position and therefore needs to take advantage of the group cash pooling arrangements. The directors have obtained a Letter of Support from its ultimate parent company Organon & Co. confirming support to enable the company to meet its liabilities when they fall due for a period of at least 12 months from the date of approval of the financial statements. The company therefore continues to adopt the going concern basis in preparing its financial statements.”
Significant events
- “The company generated a loss for the financial year of £2,023,000 due to an exceptional tax payment made in 2024 of £8,225,392, related to a tax settlement with HMRC from a historic transfer pricing inquiry.”
- “The new product Emgality, a migraine treatment, was launched in 2024, contributing to a 25% increase in turnover for the commercial portfolio.”
- “A planned medical device is being launched in 2025 for the Women's health therapy area.”
- “In January 2025, Organon Pharma UK received a refund of £2,546,000 from the Department of Health related to the VPAS 2023 scheme, treated as a post balance sheet adjusting item.”
- “Total GHG emissions and intensity ratio increased by 137% compared to the previous year, driven by a large increase in gas usage and a shift from biomass electricity to national grid electricity.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
6 active · 36 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| PARSONS, John Albert | Secretary | 2021-05-28 | — | — |
| BARR, Nicola | Director | 2025-09-01 | Aug 1976 | British |
| BITZER, Anne | Director | 2025-09-01 | Jan 1981 | French |
| LASKOWSKI, Josef Ralph | Director | 2024-03-01 | Oct 1980 | British |
| PAULOS FERREIRA ALVES DA SILVA, Sofia Raquel | Director | 2025-09-01 | Sep 1977 | Portuguese |
| WHALE, Michael | Director | 2024-03-01 | Jan 1972 | British |
Show 36 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| DALBY, Marc Charles | Secretary | 1992-08-15 | 2007-01-19 |
| DAVIES, Amy | Secretary | 2020-11-23 | 2021-06-01 |
| FADDEN, Kathleen | Secretary | — | 1992-08-15 |
| MCARDLE, Kevin Edward | Secretary | 2007-04-04 | 2011-06-28 |
| ROBINSKI, Richard | Secretary | 2011-06-28 | 2020-11-23 |
| ANSTICE, David Westbrook | Director | 1993-05-21 | 1994-10-04 |
| ARMITAGE, Robert | Director | 2003-09-19 | 2012-03-23 |
| ARMITAGE, Robert John | Director | 1993-12-10 | 2001-01-01 |
| BELL, Graeme | Director | 2009-06-23 | 2009-11-05 |
| BEYNON, Colin Bowen | Director | — | 1995-10-31 |
| BOUSFIELD, Keith | Director | 2012-03-23 | 2014-12-31 |
| BREWER, Melvyn Frederick | Director | 1995-03-22 | 1997-07-31 |
| CLIFFE, Christopher Frederick | Director | — | 1993-03-31 |
| DAHL, Torben | Director | 2021-05-28 | 2024-02-29 |
| DALBY, Marc Charles | Director | 1994-03-31 | 2007-01-19 |
| HOUSON, Louise Jane | Director | 2016-09-06 | 2019-10-01 |
| HUSSAIN, Simon Khalid | Director | 2021-05-28 | 2024-02-29 |
| IVERSEN, Leslie Lars, Professor | Director | — | 1994-03-30 |
| JACKSON, James Russell | Director | 2001-01-01 | 2003-05-31 |
| KHANNA, Deepak Kumar | Director | 2009-11-04 | 2014-06-30 |
| LANE, Richard John | Director | — | 1993-05-21 |
| LAWTON, Vincent Michael | Director | — | 2006-06-28 |
| LEONARD, Melissa | Director | 2013-12-11 | 2016-10-15 |
| LINDSEY, Sandy | Director | 2024-03-01 | 2025-05-30 |
| LITCHFIELD, Caroline Ann | Director | 2003-06-25 | 2009-06-23 |
| MCDOWELL, Mark Andrew Charles | Director | 2009-11-04 | 2013-12-31 |
| NALLY, Michael Thomas | Director | 2014-06-30 | 2016-09-30 |
| NICHOLSON, Simon | Director | 2014-12-31 | 2024-02-15 |
| PEACOCK, David | Director | 2019-10-01 | 2021-05-28 |
| POLZ, Gertraud | Director | 2016-09-06 | 2017-06-23 |
| ROUND, Christopher | Director | 2006-07-13 | 2009-11-06 |
| ROUND, Christopher | Director | 1996-06-03 | 2003-07-31 |
| TEMUCIN, Ebru Can | Director | 2017-06-23 | 2021-05-28 |
| VANDENBERK, Isabel | Director | 2024-03-01 | 2025-07-31 |
| WAKELIN, James | Director | — | 1994-04-21 |
| WHITE, Katherine Elizabeth | Director | 2014-12-31 | 2016-03-18 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Organon & Co. | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2021-06-02 | Active |
| Merck & Co., Inc. | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2021-03-22 | Ceased 2021-06-02 |
| Merck Sharp & Dohme (Uk) Limited | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2016-04-06 | Ceased 2021-03-22 |
Filing timeline
Last 20 of 252 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2025-10-03 | AA | accounts | Accounts with accounts type full | |
| 2025-09-25 | AP01 | officers | Appoint person director company with name date | |
| 2025-09-10 | AP01 | officers | Appoint person director company with name date | |
| 2025-09-10 | AP01 | officers | Appoint person director company with name date | |
| 2025-08-19 | TM01 | officers | Termination director company with name termination date | |
| 2025-07-10 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2025-06-26 | TM01 | officers | Termination director company with name termination date | |
| 2024-12-05 | PSC05 | persons-with-significant-control | Change to a person with significant control | |
| 2024-09-30 | AA | accounts | Accounts with accounts type full | |
| 2024-07-10 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2024-06-21 | AD01 | address | Change registered office address company with date old address new address | |
| 2024-06-06 | AD01 | address | Change registered office address company with date old address new address | |
| 2024-03-25 | TM01 | officers | Termination director company with name termination date | |
| 2024-03-25 | AP01 | officers | Appoint person director company with name date | |
| 2024-03-22 | TM01 | officers | Termination director company with name termination date | |
| 2024-03-22 | TM01 | officers | Termination director company with name termination date | |
| 2024-03-22 | AP01 | officers | Appoint person director company with name date | |
| 2024-03-22 | AP01 | officers | Appoint person director company with name date | |
| 2024-03-21 | AP01 | officers | Appoint person director company with name date | |
| 2023-10-05 | AA | accounts | Accounts with accounts type full |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 7
- Capital events
- 0
- Officers appointed
- 3
- Officers resigned
- 2
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.
Year-on-year
FY2023 → FY2024 · period ending 2024-12-31 vs 2023-12-31
-
Turnover
+10.1%
£138,910,000 £153,007,000
-
Cash
—
Not reported
-
Net assets
-0.1%
£105,040,000 £104,964,000
-
Employees
+5.6%
675 713
-
Operating profit
-1%
£11,119,000 £11,010,000
-
Profit before tax
-10.1%
£8,735,000 £7,850,000
-
Wages
+12.2%
£36,352,000 £40,769,000
Each % is (latest − prior) ÷ |prior| for the line item as filed. Periods don't have to be exactly 12 months apart — a long or short period (typical around incorporation or year-end changes) will distort the comparison. Lines a company doesn't report are omitted. About these numbers